|3.11 0.44 (16.48%)||12-08 16:00|
|Targets||6-month :||3.93||1-year :||4.59|
|Resists||First :||3.36||Second :||3.93|
|Supports||First :||2.39||Second :||1.78|
|MAs||MA(5) :||2.59||MA(20) :||2.15|
|MA(100) :||2.01||MA(250) :||1.49|
|MACD||MACD :||0.1||Signal :||-0.1|
|%K %D||K(14,3) :||85.3||D(3) :||80.7|
|52-week||High :||3.36||Low :||0.69|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ APLT ] has closed It is unclear right now based on current values. 85% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||3.37 - 3.38||3.38 - 3.39|
|Low:||2.54 - 2.56||2.56 - 2.57|
|Close:||3.09 - 3.11||3.11 - 3.13|
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||77 (M)|
|Shares Float||50 (M)|
|Held by Insiders||10.1 (%)|
|Held by Institutions||74.5 (%)|
|Shares Short||1,980 (K)|
|Shares Short P.Month||1,520 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||-0.15|
|Profit Margin||0 %|
|Operating Margin||-586.3 %|
|Return on Assets (ttm)||-76.7 %|
|Return on Equity (ttm)||0 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0.13|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-54 (M)|
|Levered Free Cash Flow||-20 (M)|
|Price to Book value||-22.22|
|Price to Sales||22.53|
|Price to Cash Flow||-4.45|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|